Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2025) 110 EP837 | DOI: 10.1530/endoabs.110.EP837

ECEESPE2025 ePoster Presentations Growth Axis and Syndromes (132 abstracts)

Pharmacological treatment of growth in boys with delayed or slow progression of puberty

Gunduz Ahmadov 1


1Azerbaijan Medical University, pediatric endocrinology, Baku, Azerbaijan


JOINT722

At puberty, male sexual differentiation restarts with nightly pulsatile stimulating impulses of hypothalamic gonadotropin-releasing hormone to the pituitary gland, which releases luteinizing and follicle-stimulating hormones. This nocturnal increase in gonadotropins results in growth, too. The aim of the research work was to correct the height of children the use of testosterone enanthate (TE), 50 mg intramuscularly (i.m.)/month, for the treatment of boys with delayed puberty or slow progression to induce puberty. For this purpose, 25 boys were examined. The average age of children was 13.9±1.03 years. In children, they were evaluated according to the Tanner table and measured their height, body mass and injected 0.2 ml of Omnadren-250 (testosterone, mixture of esthers). Children took this drug once a month. The boys are called back after 3 months for clinical evaluation and to follow up on pubertal and growth progression. The boys were examined by study doctors twice before the study, at inclusion, and after 3 months. After 3 months, their physical development was assessed. Physical development indicators of children are given in table 1 below. The results show that 50 mg (0.2 ml) of TE administered once every months for 3 months can be used to induce growth development in boys with delayed or slow progression of puberty, while did not record an honest increase in body mass.

Table 1. Indicators of physical development of children
Parameters Before After p
Height144,4±4,83147,1±4,45p<0,0001
Weight36,5±7,0339,0±6,62p>0,05
SD Height-2,3±0,25-2,1±0,23p<0,0001
SD Weight-0,9±1,39-0,7±1,24p>0,05
BMİ kq/m217,5±3,1017,9±2,77p>0,05
Body percent %78,7±21,0786,4±12,89p>0,05

Volume 110

Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) 2025: Connecting Endocrinology Across the Life Course

European Society of Endocrinology 
European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches